Basilea Pharmaceutica

We look forward to tomorrow's panel discussion organized by Life Science Zurich Young Scientist Network! Our Chief Scientific Officer, Dr. Laurenz Kellenberger, will join the conversation on “From Labs To Legislation: Breaking Antimicrobial Resistance” at University of Zurich, along with three other experts in the field. If you are in Zurich and interested in #AMR, don't miss it!

We are very happy about partnering with the Biomedical Advanced Research and Development Authority (BARDA), for the development of new #antifungals and #antibacterials. This will help us to further address the critical medical needs of patients. 🎥 In this interview with BiotechTV, our CEO David Veitch, describes why this news is a confirmation of the strength of Basilea's portfolio and business model.

Secondary infections caused by drug-resistant fungi can complicate patient treatment during a public health emergency, which is why developing new therapeutic options is critical. In support of Fungal Disease Awareness Week, we are pleased to announce our partnership with Basilea Pharmaceutica to advance the development of two antifungal candidates: Fosmanogepix, a broad-spectrum antifungal, and BAL2062, a candidate intended to treat invasive Aspergillus infections. Learn more about our first contract to develop antifungal therapeutics: https://ow.ly/cqbX50TqqeW

Basilea receives BARDA funding to advance development of two #new #antifungals Today we announced that Basilea was awarded an Other Transaction Agreement (OTA) by the Biomedical Advanced Research and Development Authority (BARDA) to support the development of first-in-class antifungals and #antibacterials. Basilea received an initial funding of USD 29 million for the development of its clinical stage antifungals, fosmanogepix and BAL2062, with an option for more funding to develop Basilea’s portfolio. David Veitch, CEO of #BasileaPharmaceutica, said: “Basilea has been working with BARDA since 2013. In continuing this partnership through an OTA, we will be leveraging our strong portfolio and the capabilities of our organization to develop urgently needed novel antifungals and antibacterials.” Find more information in our #PressRelease: https://lnkd.in/eX8dp-dK

We look forward to attending #Pareto Securities' 15th Annual Healthcare Conference in Stockholm on 19 September 2024! The conference provides an excellent opportunity to get insights into the latest developments in the #healthcare industry, attend one-on-one #investor meetings, and mingle with industry professionals from #Pharma, #Biotech, and Medtech in person. ⭐ CALL TO INVESTORS ⭐ Our CEO David Veitch and CFO Adesh Kaul will present Basilea, a few one-on-one meetings slots are still available! Please contact Pareto’s event team via events.se@paretosec.com. We would be delighted to see you there and have a chat!

Our #antifungal Cresemba continues to meet the critical medical needs of #patients with life-threatening invasive mold infections. Recently we were able to report two major successes for Cresemba in #Europe: 🏥 In August 2024, Cresemba, which in Europe was so far only approved for adults, was approved for the use in #children who suffer from invasive aspergillosis or mucormycosis. This approval by the European Commission goes along with an extension of market exclusivity by two additional years and a milestone payment to Basilea. 🏆 Today, we were able to report a continued strong sales performance of Cresemba in Europe. Sales exceeded the threshold that triggered a milestone payment of USD 25 million to Basilea. #Congratulations to all teams involved and thank you to our partners for helping us addressing patients needs!

We are happy to be part of the Switzerland Innovation Park Basel Area ecosystem. Working in close proximity with large and small players in the Life Sciences Hub Basel Area is incredibly valuable and inspiring.

We are #hiring! Please click on the job advertisement below for further information.

We are #hiring! Please click on the job advertisement below for further information.